Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

Abstract

Our study demonstrates that the IGF1R/p110β/AKT/mTOR axis confers resistance to BYL719 in PIK3CA mutant breast cancers. This provides a rationale for the combined targeting of p110α with IGF1R or p110β in patients with breast tumors harboring PIK3CA mutations.